Personalized cancer vaccine trial halted before launch
NCT ID NCT05799612
Summary
This was an early, withdrawn study to test the safety of a personalized vaccine for a rare and aggressive skin cancer called angiosarcoma. The vaccine would have been made from a patient's own immune cells and tumor tissue. The main goal was to find a safe dose and see if the body's immune system could be trained to fight the cancer after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.